Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control
- PMID: 40769148
- DOI: 10.1016/j.cmet.2025.07.006
Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control
Abstract
Glucose is essential for T cell proliferation and function, yet its specific metabolic roles in vivo remain poorly defined. Here, we identify glycosphingolipid (GSL) biosynthesis as a key pathway fueled by glucose that enables CD8+ T cell expansion and cytotoxic function in vivo. Using 13C-based stable isotope tracing, we demonstrate that CD8+ effector T cells use glucose to synthesize uridine diphosphate-glucose (UDP-Glc), a precursor for glycogen, glycan, and GSL biosynthesis. Inhibiting GSL production by targeting the enzymes UDP-Glc pyrophosphorylase 2 (UGP2), UDP-Gal-4-epimerase (GALE), or UDP-Glc ceramide glucosyltransferase (UGCG) impairs CD8+ T cell expansion upon pathogen challenge. Mechanistically, we show that glucose-dependent GSL biosynthesis is required for plasma membrane lipid raft integrity and optimal T cell receptor (TCR) signaling. Moreover, UGCG-deficient CD8+ T cells display reduced granzyme expression, cytolytic activity, and tumor control in vivo. Together, our data establish GSL biosynthesis as a critical metabolic fate of glucose-beyond energy production-that is required for CD8+ T cell responses in vivo.
Keywords: CD8(+) T cells; UGCG; cytotoxic function; glucose; glycosphingolipids; immunometabolism; lipid rafts; lipidomics; metabolomics; nucleotide sugar metabolism.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.G.J. is a scientific advisor to Servier Pharmaceuticals and is a member of the Scientific Advisory Board of Immunomet Therapeutics.
Update of
-
Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control.bioRxiv [Preprint]. 2024 Oct 14:2024.10.10.617261. doi: 10.1101/2024.10.10.617261. bioRxiv. 2024. Update in: Cell Metab. 2025 Jul 30:S1550-4131(25)00333-X. doi: 10.1016/j.cmet.2025.07.006. PMID: 39464161 Free PMC article. Updated. Preprint.
Similar articles
-
Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function and tumor control.bioRxiv [Preprint]. 2024 Oct 14:2024.10.10.617261. doi: 10.1101/2024.10.10.617261. bioRxiv. 2024. Update in: Cell Metab. 2025 Jul 30:S1550-4131(25)00333-X. doi: 10.1016/j.cmet.2025.07.006. PMID: 39464161 Free PMC article. Updated. Preprint.
-
Selective requirement of glycosphingolipid synthesis for natural killer and cytotoxic T cells.Cell. 2025 Jun 26;188(13):3497-3512.e16. doi: 10.1016/j.cell.2025.04.007. Epub 2025 Apr 29. Cell. 2025. PMID: 40306279
-
Glycolytic PFKFB3 and Glycogenic UGP2 Axis Regulates Perfusion Recovery in Experimental Hind Limb Ischemia.Arterioscler Thromb Vasc Biol. 2024 Aug;44(8):1764-1783. doi: 10.1161/ATVBAHA.124.320665. Epub 2024 Jun 27. Arterioscler Thromb Vasc Biol. 2024. PMID: 38934117 Free PMC article.
-
T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.J Virol. 2025 Aug 5:e0018825. doi: 10.1128/jvi.00188-25. Online ahead of print. J Virol. 2025. PMID: 40762498
-
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536. Health Technol Assess. 2024. PMID: 39673446 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous